OBJECTIVE: We aimed to evaluate the efficacy and safety of oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) (FOLFOX-4) as second-line treatment in patients with advanced biliary tract cancer (BTC) failinggemcitabine/cisplatin first-line chemotherapy. METHODS:Thirty-seven patients with advanced BTC refractory togemcitabine/cisplatin chemotherapy were included in the study. FOLFOX-4 regimen consisted of oxaliplatin (85 mg/m(2)) as a 2-hour infusion on day 1 and 2-hour infusion of LV (200 mg/m(2)/day) followed by a 5-FU bolus (400 mg/m(2)/day) and 22-hour infusion of 5-FU (600 mg/m(2)/day) for two consecutive days every 2 weeks. The primary end point was the time to progression (TTP). RESULTS:Between January 2009 and January 2012, a total of 37 patients were enrolled. The median age was 57 years (range 32-70) and male to female ratio was 21:16. Median TTP was 3·1 months (95% CI 2·3-3·6). The objective response rate was 21·6% (eight partial responses), and disease control rate was 62·2% (15 stable disease). Grade 3-4 toxicities were observed in 37·8% of the patients with neutropenia and fatigue being the most frequent (21·6%). CONCLUSIONS: FOLFOX-4 regimen is a feasible and moderately efficacious second-line chemotherapy for advanced BTC.
RCT Entities:
OBJECTIVE: We aimed to evaluate the efficacy and safety of oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) (FOLFOX-4) as second-line treatment in patients with advanced biliary tract cancer (BTC) failing gemcitabine/cisplatin first-line chemotherapy. METHODS: Thirty-seven patients with advanced BTC refractory to gemcitabine/cisplatin chemotherapy were included in the study. FOLFOX-4 regimen consisted of oxaliplatin (85 mg/m(2)) as a 2-hour infusion on day 1 and 2-hour infusion of LV (200 mg/m(2)/day) followed by a 5-FU bolus (400 mg/m(2)/day) and 22-hour infusion of 5-FU (600 mg/m(2)/day) for two consecutive days every 2 weeks. The primary end point was the time to progression (TTP). RESULTS: Between January 2009 and January 2012, a total of 37 patients were enrolled. The median age was 57 years (range 32-70) and male to female ratio was 21:16. Median TTP was 3·1 months (95% CI 2·3-3·6). The objective response rate was 21·6% (eight partial responses), and disease control rate was 62·2% (15 stable disease). Grade 3-4 toxicities were observed in 37·8% of the patients with neutropenia and fatigue being the most frequent (21·6%). CONCLUSIONS:FOLFOX-4 regimen is a feasible and moderately efficacious second-line chemotherapy for advanced BTC.
Entities:
Keywords:
Biliary tract cancer,; Cisplatin,; FOLFOX-4,; Gemcitabine,; Second line
Authors: Annekathrin Roth; Eberhard Schleyer; Konrad Schoppmeyer; Regine Kluge; Christian Wittekind; Joachim Mössner; Marcus Wiedmann Journal: Onkologie Date: 2011-08-22
Authors: E Gabriela Chiorean; Rashmi Ramasubbaiah; Menggang Yu; Joel Picus; Jose A Bufill; Yan Tong; Nicki Coleman; Erica L Johnston; Colleen Currie; Patrick J Loehrer Journal: Oncologist Date: 2011-12-30
Authors: Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater Journal: N Engl J Med Date: 2010-04-08 Impact factor: 91.245
Authors: Anna-Liisa Kautio; Maija Haanpää; Hannu Kautiainen; Arto Leminen; Eija Kalso; Tiina Saarto Journal: Anticancer Res Date: 2011-10 Impact factor: 2.480
Authors: Jun Ho Yi; Sumitra Thongprasert; Jeeyun Lee; D C Doval; Se Hoon Park; Joon Oh Park; Young Suk Park; Won Ki Kang; Ho Yeong Lim Journal: Eur J Cancer Date: 2011-12-14 Impact factor: 9.162
Authors: Andrew X Zhu; Jeffrey A Meyerhardt; Lawrence S Blaszkowsky; Avinash R Kambadakone; Alona Muzikansky; Hui Zheng; Jeffrey W Clark; Thomas A Abrams; Jennifer A Chan; Peter C Enzinger; Pankaj Bhargava; Eunice L Kwak; Jill N Allen; Sanjay R Jain; Keith Stuart; Kerry Horgan; Susan Sheehan; Charles S Fuchs; David P Ryan; Dushyant V Sahani Journal: Lancet Oncol Date: 2009-11-20 Impact factor: 41.316
Authors: Richard Kim; E Gabriela Chiorean; Manik Amin; Caio Max S Rocha-Lima; Jitendra Gandhi; William P Harris; Tao Song; David Portnoy Journal: Br J Cancer Date: 2017-06-20 Impact factor: 7.640